Nonalcoholic Fatty Liver
Nonalcoholic Fatty Liver - Related Videos
11:08
The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
0 Views •
Cited by 71 •
2014
Pregnancy leads to significant changes to the fatty acid composition of maternal tissues. Lipid profiles can be obtained via gas chromatography to allow identification and quantification of fatty acids in individual lipid classes among rats fed various high and low fat diets during pregnancy.
09:27
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
0 Views •
Cited by 8 •
2021
Here, we present how to generate a non-alcoholic fatty liver disease (NAFLD)-associated Hepatocellular Carcinoma (HCC) zebrafish model to study the impact of cholesterol surplus on liver microenvironment and immune cell landscape.
06:03
Quantification of Endothelial Fatty Acid Uptake using Fluorescent Fatty Acid Analogs
0 Views •
2025
This protocol details an in vitro assay for measuring cellular lipid uptake in endothelial cells upon stimulation with BODIPY-C12 and BODIPY-C16 fluorescent analogs of long-chain and very long-chain saturated fatty acids. This method is efficient and adaptable to other cell types, offering a useful approach for studying lipid metabolism.
12:35
In vivo Liver Endocytosis Followed by Purification of Liver Cells by Liver Perfusion
0 Views •
Cited by 14 •
2011
The study of liver sinusoidal endothelial cells (SECs) must be performed with primary cells obtained from the animal as no cell lines exist. This method relies on liver digestion and differential centrifugation for SEC purification for subsequent culturing and experimentation.
12:11
Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes
0 Views •
Cited by 39 •
2015
De novo lipogenesis and β-fatty acid oxidation constitute key metabolic pathways in hepatocyte, pathways that are perturbed in several metabolic disorders, including fatty liver disease. Here we demonstrate isolation of mouse primary hepatocytes and describe quantification of β-fatty acid oxidation and lipogenesis.
FAQs
Insulin resistance alters normal metabolic regulation, increasing the delivery of fatty acids to the liver and promoting lipid storage within liver cells. This metabolic disturbance helps explain why the condition is associated with broader metabolic dysfunction rather than being limited to an isolated liver abnormality. It also creates conditions that may support subsequent inflammation and fibrosis.
Simple steatosis represents fat accumulation without necessarily indicating the full spectrum of liver injury. In some people, stored lipid is associated with inflammation, producing nonalcoholic steatohepatitis, or NASH. Continued injury may promote fibrosis, and advanced disease can progress to cirrhosis and liver cancer. This range makes disease stage clinically important.
Inflammation reflects liver injury that may arise after metabolic dysfunction increases lipid storage and fatty-acid delivery. Fibrosis is the formation of scar tissue associated with ongoing injury, and its presence helps distinguish a more consequential disease state from uncomplicated steatosis. Evaluating fibrosis is therefore important for estimating progression and guiding monitoring.
Assessment considers three connected areas: metabolic risk factors, evidence of liver injury, and the degree of fibrosis. Looking at these domains together helps place a person along the disease spectrum, from relatively limited steatosis to more advanced liver disease. The resulting assessment supports decisions about monitoring and the need to address progression risk.
Management centers on addressing metabolic risk factors while evaluating liver injury and fibrosis. This combined approach recognizes that reducing concern about fat storage alone is insufficient when inflammation or scarring may be present. Clinical planning uses the assessment findings to guide monitoring and to reduce the likelihood that disease will progress toward advanced liver complications.
Monitoring is particularly relevant when assessment indicates liver injury or fibrosis, because the condition can extend from steatosis to NASH, cirrhosis, and liver cancer. In medicine, tracking metabolic risk factors alongside liver status helps identify a changing disease course and keeps management focused on limiting progression and recognizing more advanced disease.